Cargando…
Commentary: Intravitreal moxifloxacin for acute postoperative endophthalmitis: Is it as safe and efficacious as the age-old recommended intravitreal vancomycin and ceftazidime?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933857/ https://www.ncbi.nlm.nih.gov/pubmed/33463585 http://dx.doi.org/10.4103/ijo.IJO_2489_20 |
| _version_ | 1783660704243384320 |
|---|---|
| author | Bhojwani, Deepak |
| author_facet | Bhojwani, Deepak |
| author_sort | Bhojwani, Deepak |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7933857 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Wolters Kluwer - Medknow |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79338572021-03-08 Commentary: Intravitreal moxifloxacin for acute postoperative endophthalmitis: Is it as safe and efficacious as the age-old recommended intravitreal vancomycin and ceftazidime? Bhojwani, Deepak Indian J Ophthalmol Commentary Wolters Kluwer - Medknow 2021-02 /pmc/articles/PMC7933857/ /pubmed/33463585 http://dx.doi.org/10.4103/ijo.IJO_2489_20 Text en Copyright: © 2021 Indian Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
| spellingShingle | Commentary Bhojwani, Deepak Commentary: Intravitreal moxifloxacin for acute postoperative endophthalmitis: Is it as safe and efficacious as the age-old recommended intravitreal vancomycin and ceftazidime? |
| title | Commentary: Intravitreal moxifloxacin for acute postoperative endophthalmitis: Is it as safe and efficacious as the age-old recommended intravitreal vancomycin and ceftazidime? |
| title_full | Commentary: Intravitreal moxifloxacin for acute postoperative endophthalmitis: Is it as safe and efficacious as the age-old recommended intravitreal vancomycin and ceftazidime? |
| title_fullStr | Commentary: Intravitreal moxifloxacin for acute postoperative endophthalmitis: Is it as safe and efficacious as the age-old recommended intravitreal vancomycin and ceftazidime? |
| title_full_unstemmed | Commentary: Intravitreal moxifloxacin for acute postoperative endophthalmitis: Is it as safe and efficacious as the age-old recommended intravitreal vancomycin and ceftazidime? |
| title_short | Commentary: Intravitreal moxifloxacin for acute postoperative endophthalmitis: Is it as safe and efficacious as the age-old recommended intravitreal vancomycin and ceftazidime? |
| title_sort | commentary: intravitreal moxifloxacin for acute postoperative endophthalmitis: is it as safe and efficacious as the age-old recommended intravitreal vancomycin and ceftazidime? |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933857/ https://www.ncbi.nlm.nih.gov/pubmed/33463585 http://dx.doi.org/10.4103/ijo.IJO_2489_20 |
| work_keys_str_mv | AT bhojwanideepak commentaryintravitrealmoxifloxacinforacutepostoperativeendophthalmitisisitassafeandefficaciousastheageoldrecommendedintravitrealvancomycinandceftazidime |